| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AZ628 | GDSC1000 | pan-cancer | AAC | 0.0091 | 0.8 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0071 | 0.8 |
| mRNA | ISOX | CTRPv2 | pan-cancer | AAC | -0.006 | 0.8 |
| mRNA | MS-275 | gCSI | pan-cancer | AAC | 0.0095 | 0.9 |
| mRNA | ML312 | CTRPv2 | pan-cancer | AAC | 0.014 | 0.9 |
| mRNA | tubastatin A | CTRPv2 | pan-cancer | AAC | 0.0091 | 0.9 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | 0.006 | 0.9 |
| mRNA | vorapaxar | CTRPv2 | pan-cancer | AAC | -0.0067 | 0.9 |
| mRNA | Pyrimethamine | GDSC1000 | pan-cancer | AAC | 0.0091 | 0.9 |
| mRNA | ciclosporin | CTRPv2 | pan-cancer | AAC | -0.0066 | 0.9 |